StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note published on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences has a 52 week low of $0.00 and a 52 week high of $0.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35. The company has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Featured Articles
- Five stocks we like better than Genocea Biosciences
- Bank Stocks – Best Bank Stocks to Invest In
- MarketBeat Week in Review – 4/29 – 5/3
- Which Wall Street Analysts are the Most Accurate?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Consumer Staples Stocks, Explained
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.